OGN News and Press, Organon & Co. From 11/11/21

Organon & Co. (OGN) Q3 Earnings Conference Call November 11, 2021, 8:30 AM ET Company Participants Kevin Ali – Chief Executive Officer Jennifer Halchak – Vice President, Investor Relations Matt Walsh – Chief Financial Officer Conference Call Participants Chris Schott ...

The following slide deck was published by Organon & Co. in conjunction with their 2021 Q3 earnings call. For further details see: Organon & Co. 2021 Q3 - Results - Earnings Call Presentation

Organon (NYSE:OGN) is trading flat in the pre-market after the company reported Q3 2021 financials exceeding analyst expectations. Merck spinoff focused on women’s health and biosimilars also narrowed its full-year guidance. For the quarter, the topline dipped ~1% YoY to $1.6B aft...

Organon (NYSE:OGN) declares $0.28/share quarterly dividend, in line with previous. Forward yield 3.06% Payable Dec. 16; for shareholders of record Nov. 22; ex-div Nov. 19. See OGN Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Organon declares $0.28 div...

Organon (NYSE:OGN): Q3 Non-GAAP EPS of $1.67 beats by $0.23; GAAP EPS of $1.27 beats by $0.07. Revenue of $1.6B (-0.6% Y/Y) beats by $10M. Press Release For further details see: Organon EPS beats by $0.23, beats on revenue

Third quarter 2021 revenue of $1,600 million Net income from continuing operations of $323 million, or $1.27 per diluted share; Adjusted net income from continuing operations of $424 million, or $1.67 per diluted share Adjusted EBITDA of $636 million Board of Dir...

Acquisition adds pipeline of candidates targeting novel treatments in women’s health Organon (NYSE: OGN), and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug de...

Organon (NYSE:OGN) is scheduled to announce Q3 earnings results on Thursday, November 11th, before market open. The consensus EPS Estimate is $1.44 and the consensus Revenue Estimate is $1.59B. Organon shares traded ~4% higher after the company swung back to growth with better than&...

Merck fell almost 10% on Friday after Pfizer announced its own antiviral pill. The stock is now up less than 10% after its pre-antiviral announcement levels, offering an attractive entry point. Merck could earn upwards to $1 per share in incremental EPS from its molnupiravir Covid...

NEXPLANON® (etonogestrel extended-release subdermal implant) Now Covered by Quebec's Public Formulary Canada NewsWire Public reimbursement is effective on November 10 th . KIRKLAND, QC , Nov. 8, 2021 /CNW/ - Organon (NYSE: OGN) is pleased to ...